DelveInsight’s, “Multiple sclerosis Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the Multiple Sclerosis pipeline drug profiles, including Multiple Sclerosis clinical trials and nonclinical stage products. It also covers the Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Multiple Sclerosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Multiple Sclerosis NDA approvals (if any), and product development activities comprising the technology, Multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Multiple Sclerosis Pipeline treatment landscape of the report, click here @ Multiple Sclerosis Pipeline Outlook

 

Key Takeaways from the Multiple Sclerosis Pipeline Report

• DelveInsight’s Multiple Sclerosis Pipeline analysis depicts a robust space with 100+ active players working to develop 100+ pipeline treatment therapies.
• The leading Multiple Sclerosis Companies are working in the market include TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others
• Emerging Multiple Sclerosis Pipeline Therapies in the various stages of development include rHIgM22, CNTO 1275, Interferon beta-1a (Rebif), alemtuzumab, IMS001, ALKS 8700, Curcumin, and others
• On March 2023, Innodem Neurosciences has announced drug named Eye-Tracking. This study aims to develop and validate a sensitive and non-invasive eye-tracking software application.
• On September 2022, ImStem Biotechnology has announced drug named IMS001 by the phase 1. This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the potential to modulate disease course.

 

Multiple Sclerosis Overview

Multiple sclerosis (MS) is a chronic disease affecting the central nervous system (the brain and spinal cord).MS occurs when the immune system attacks nerve fibers and myelin sheathing (a fatty substance which surrounds/insulates healthy nerve fibers) in the brain and spinal cord. This attack causes inflammation, which destroys nerve cell processes and myelin – altering electrical messages in the brain.

 

For further information, refer to the detailed Multiple Sclerosis Unmet Needs, Multiple Sclerosis Market Drivers, and Market Barriers, click here for Multiple Sclerosis Ongoing Clinical Trial Analysis

 

Multiple Sclerosis Emerging Drugs Profile

• Ublituximab: TG Therapeutics
• IMU-838: Immunic
• ATA188: Atara Biotherapeutics
• ANK-700: ANOKION

 

Multiple Sclerosis Pipeline Therapeutics Assessment

There are approx. 100+ Multiple Sclerosis companies which are developing the therapies for Multiple sclerosis. The Multiple Sclerosis companies which have their Multiple sclerosis drug candidates in the most advanced stage, i.e. preregistration include, TG Therapeutics.

 

Request a sample and discover the recent advances in Multiple Sclerosis Ongoing Clinical Trial Analysis and Medications, click here @ Multiple Sclerosis Treatment Landscape

 

Multiple Sclerosis Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Multiple Sclerosis Therapeutics Market include-

TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.

 

Dive deep into rich insights for drugs for Multiple Sclerosis Pipeline, click here @ Multiple Sclerosis Unmet Needs and Analyst Views

 

Scope of the Multiple Sclerosis Pipeline Report

• Coverage- Global
• Multiple Sclerosis Companies- TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
• Multiple Sclerosis Therapies- rHIgM22, CNTO 1275, Interferon beta-1a (Rebif), alemtuzumab, IMS001, ALKS 8700, Curcumin, and others
• Multiple Sclerosis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Multiple Sclerosis Merger and acquisitions, Multiple Sclerosis Licensing Activities @ Multiple Sclerosis Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Multiple Sclerosis Executive Summary
3. Multiple sclerosis: Overview
4. Multiple Sclerosis Pipeline Therapeutics
5. Multiple Sclerosis Therapeutic Assessment
6. Multiple sclerosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Ublituximab: TG Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EHP 101: Emerald Health Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ASLAN 003: ASLAN Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Lucid MS: FSD Pharma
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Multiple sclerosis Key Companies
21. Multiple sclerosis Key Products
22. Multiple sclerosis- Unmet Needs
23. Multiple sclerosis- Market Drivers and Barriers
24. Multiple sclerosis- Future Perspectives and Conclusion
25. Multiple sclerosis Analyst Views
26. Multiple sclerosis Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services